244
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Change of Nrf2 expression in rat hippocampus in a model of chronic cerebral hypoperfusion

, , &
Pages 577-584 | Received 21 Apr 2013, Accepted 03 Nov 2013, Published online: 04 Dec 2013
 

Abstract

Chronic cerebral hypoperfusion (CCH) is common in vascular dementia and Alzheimer's disease. CCH-related oxidative damage plays a significant role in the development of cognitive impairment. Nuclear factor-erythroid 2-related factor-2 (Nrf2) mediates activation of the antioxidant responsive element (ARE)-related gene expression, which is crucial to the endogenous antioxidative system. In this case, we used permanent bilateral occlusion of common carotid arteries (2VO) to mimic CCH. The expression of Nrf2 in different regions of the hippocampus as well as the ability of nuclear Nrf2 and ARE binding have been examined. A phenomenon has been observed that the DNA binding activities were down-regulated. Interestingly, the expression of Nrf2 rose significantly in most regions of rat hippocampus within three weeks after the 2VO surgery. The mismatch might attribute to Nrf2 dysfunction and compensatory synthesis. A conclusion can be drawn that Nrf2 dysfunction is an important factor as a cause of CCH-induced oxidative damage and Nrf2 can be treated as a promising target to alleviate oxidative damage, even cognitive impairment caused by CCH.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.